Compile Data Set for Download or QSAR
Report error Found 41 Enz. Inhib. hit(s) with all data for entry = 451
TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270491(US10059668, Example 55)
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270481(US10059668, Example 44)
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270475(US10059668, Example 38)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270453(US10059668, Example 16)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270464(US10059668, Example 37 | US10059668, Example 27)
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270488(US10059668, Example 52)
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270490(US10059668, Example 54)
Affinity DataIC50: 9nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270443(US10059668, Example 6)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270442(US10059668, Example 5)
Affinity DataIC50: 10nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270461(US10059668, Example 24)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270487(US10059668, Example 51)
Affinity DataIC50: 11nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270484(US10059668, Example 47)
Affinity DataIC50: 12nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270463(US10059668, Example 26)
Affinity DataIC50: 12nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270482(US10059668, Example 45)
Affinity DataIC50: 13nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270467(US10059668, Example 42 | US10059668, Example 30)
Affinity DataIC50: 14nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270460(US10059668, Example 23)
Affinity DataIC50: 14nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270456(US10059668, Example 19)
Affinity DataIC50: 16nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270446(US10059668, Example 9)
Affinity DataIC50: 17nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270486(US10059668, Example 50)
Affinity DataIC50: 20nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270466(US10059668, Example 40 | US10059668, Example 29)
Affinity DataIC50: 21nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270448(US10059668, Example 11)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270476(US10059668, Example 39)
Affinity DataIC50: 25nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270444(US10059668, Example 7)
Affinity DataIC50: 26nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270445(US10059668, Example 8)
Affinity DataIC50: 27nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270483(US10059668, Example 46)
Affinity DataIC50: 29nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270447(US10059668, Example 10)
Affinity DataIC50: 33nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270465(US10059668, Example 36 | US10059668, Example 28)
Affinity DataIC50: 39nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270457(US10059668, Example 20)
Affinity DataIC50: 42nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270492(US10059668, Example 56)
Affinity DataIC50: 43nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270462(US10059668, Example 25)
Affinity DataIC50: 48nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270454(US10059668, Example 17)
Affinity DataIC50: 51nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270455(US10059668, Example 18)
Affinity DataIC50: 55nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270464(US10059668, Example 37 | US10059668, Example 27)
Affinity DataIC50: 58nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270468(US10059668, Example 41 | US10059668, Example 31)
Affinity DataIC50: 69nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270470(US10059668, Example 33)
Affinity DataIC50: 69nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270465(US10059668, Example 36 | US10059668, Example 28)
Affinity DataIC50: 81nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270466(US10059668, Example 40 | US10059668, Example 29)
Affinity DataIC50: 98nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270469(US10059668, Example 32)
Affinity DataIC50: 122nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270467(US10059668, Example 42 | US10059668, Example 30)
Affinity DataIC50: 127nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270466(US10059668, Example 40 | US10059668, Example 29)
Affinity DataIC50: 133nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent

TargetLysine-specific histone demethylase 1A(Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM270468(US10059668, Example 41 | US10059668, Example 31)
Affinity DataIC50: 144nMpH: 7.5 T: 2°CAssay Description:Briefly, compounds of the present invention were solubilized in DMSO and a series of 10, three-fold serial dilutions were made for each compound in 1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/11/2018
Entry Details
Go to US Patent